Imago’s main prize is bomedemstat, a drug candidate that’s in phase 2 trials for multiple blood disorders including essential thrombocythemia, myelofibrosis and polycythemia vera.
The transaction, which will merge Merck’s acquisition subsidiary and Imago, is expected to be finalized in the first quarter of 2023.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
